Ignite Creation Date:
2024-05-06 @ 8:02 AM
Last Modification Date:
2024-10-26 @ 11:55 AM
Study NCT ID:
NCT02658409
Status:
UNKNOWN
Last Update Posted:
2016-02-26
First Post:
2015-12-06
Brief Title:
A Multicenter Double-blind Parallel Non-inferiority Phase III Study
Sponsor:
Green Cross Corporation
Organization:
GC Biopharma Corp
Study Overview
Official Title:
A Multicenter Randomized Double-blind Active-controlled Parallel Non-inferiority Phase III Study to Investigate the Efficacy Immunogenicity and Safety of GC3106 Quadrivalent Cell-culture Based Influenza Vaccine
Status:
UNKNOWN
Status Verified Date:
2016-01
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Multicenter Randomized Double-blind Active-controlled Parallel Non-inferiority Phase III Study
Detailed Description:
A Multicenter Randomized Double-blind Active-controlled Parallel Non-inferiority Phase III Study to Investigate the Efficacy Immunogenicity and Safety of GC3106 quadrivalent cell-culture based influenza vaccine after Intramuscular Administration in Healthy Subjects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None